- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Solid Tumor Profile Plus™ combines broad DNA analysis with targeted transcriptome sequencing to deliver comprehensive molecular profiling for solid tumors, supporting diagnosis, prognosis, therapy selection, biomarker discovery, and precision treatment strategies.
Solid Tumor Profile Plus™ is a comprehensive DNA and RNA assay designed to deliver an in-depth molecular evaluation of cancer. By combining analysis of more than 400 DNA genes with targeted transcriptome sequencing of more than 1,600 RNA genes, it detects single-nucleotide variants, copy-number changes, gene fusions, gene expression patterns, MSI, TMB, HRR mutations, and HRD. The assay also includes clinically relevant features such as MET exon 14 skipping, EGFRvIII, AR-V7, TERT promoter mutations, DPYD polymorphisms, and immune-related RNA markers including CTLA4, PD-L1, and PD-L2, helping support prognosis, therapy selection, and prediction of response to immunotherapies, targeted therapies, and other precision treatment strategies.
Solid Tumor Profile Plus™ provides broad genomic and transcriptomic profiling for solid tumors in a single assay. It is designed to generate actionable molecular insights that support diagnosis, prognostic assessment, treatment planning, biomarker discovery, and clinical trial matching, while also offering advanced capabilities such as fusion detection, exon skipping, alternative splicing analysis, HLA class I genotyping, viral detection, and optional MGMT methylation testing for brain cancer patients.
The Solid Tumor Profile Plus test combines the analysis of >400 DNA genes with targeted transcriptome sequencing (RNA) of >1600 genes to provide a comprehensive evaluation of cancer that includes detection of single-nucleotide variation, copy-number variation, gene expression levels, and fusions irrespective of their partner genes. In addition, the test is designed to detect microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair (HRR) mutations, and homologous recombination deficiency (HRD).
Other notable features include evaluation for MET exon 14 skipping, EGFRvIII, AR-V7, TERT promoter mutations, DYPD gene polymorphism for prediction of toxicity to fluoropyrimidine therapy, and RNA levels of CTLA4, PD-L1, and PD-L2. The provided information helps in determining prognosis, designing a therapeutic approach, and predicting response to immunotherapies, targeted therapies, and precision medicines. It may also aid in biomarker discovery.
The test covers >400 DNA genes and >1600 RNA genes.
Sensitivity is 3% for non-hotspot and 1% for hotspots. It is at 0.001 for cases with prior Hx.Epstein-Barr Virus (EBV): Important for diagnosis and classification of lymphoid neoplasms and some solid tumors.
Human Papillomavirus (HPV): Chronic infection with high-risk HPV subtypes is associated with increased risk of anogenital and oropharyngeal cancer. Detection of HPV mRNA suggests active (productive) infection.
Torque Teno Virus (TTV): This virus was first discovered in a patient with non-A-E hepatitis and is now regarded as a part of the human virome. In general, TTV does not cause pathology in immunocompetent individuals. This virus is considered as a marker of the degree of immune competence in patients with immunological impairment and inflammatory disorders. High TTV load is associated with increased risk of infection. In patients with organ transplant, low TTV load is associated with an increased risk of rejection.
T-cell and B-cell Clonality Detection: The detection of T- and B-cell clonality is important because it can help diagnose and monitor certain types of malignancies. When a malignant transformation occurs in a T- or B-cell, the cells can undergo uncontrolled clonal expansion, resulting in the accumulation of many cells with the identical T- or B-cell receptor.
MGMT Methylation: This assay is available as an add-on for brain cancer patients. MGMT methylation is predictive of response to radiotherapy and prognostic for glioblastoma.
Real-world applications of our genomic testing
We provide a selection of real-world case studies that demonstrate the clinical utility and diagnostic impact of our genomic tests. Click the button below to explore individual cases and see how Solid Tumor Profile Plus™ contributes to precision oncology in practice.
Our case study list is continuously updated as new clinical examples become available. We encourage you to revisit this page regularly to explore the latest insights and applications of our genomic testing in real-world settings.
- FFPE: 1 H&E slide and 8-10 unstained slides, 5-7 microns of BM clot or tissue fixed with 10% NBF fixative. Alternatively, the FFPE block of the BM clot can be sent for sectioning in our Lab.
- Alternatively, the FFPE block can be sent for tumor circling and cutting at our laboratory.
This is a brief overview of the sample requirements for this test. For complete and detailed instructions regarding specimen collection, handling, and submission, please download the full sample guidelines by clicking the button below.
Specimen Preparation and Shipping Guidelines
Use the Solid Tumor Transport Kit
For FFPE samples:
Fill out the form to request kits. Please refer to the Specimen Requirements page for more details.
*GTC will need to set you up in our system if this is your first order.
